A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Dr Hannah McManus looks ahead to the release of new data from phase 3 clinical trials that will inform multidisciplinary ...

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically ...

These results correspond to an 80% reduction in the risk of death among patients surviving beyond five years.

PSMA-PET scans detected metastatic disease in 46% of patients, indicating understaging by conventional imaging in high-risk nonmetastatic hormone-sensitive prostate cancer. The study involved 182 ...

But a practice called integrative medicine, which combines conventional cancer therapies with complementary and holistic treatments, is increasingly being used to manage the disease. While ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Credit: Getty Images Investigators explore the biomarker potential of circulating tumor DNA and tumor suppressor gene status. Elevated circulating tumor DNA fraction and tumor suppressor gene loss are ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...